Receptagen deal

RCG said it plans to acquire privately held Ryan Pharmceuticals Inc. for 750,000 shares of RCG and a 5 percent royalty on the net sales of Coenzyme Q10, a potential immune stimulant to which Ryan owns the exclusive U.S. patent.

In addition, RCG will pay Ryan's shareholders $15,000 up front and then up to $200,000 for expenses incurred in connection with the patent. Ryan will be a wholly owned subsidiary of RCG. ...